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Abstract: Effective management of schizophrenia remains a significant clinical challenge. 
While antipsychotic medications have proven efficacy in this disease, there remains an opportunity 
to further improve symptom control and long-term relapse prevention. Also, a   number of factors, 
including tolerability and complex dosing regimens, can result in   nonadherence to medication. 
Quetiapine is an atypical antipsychotic with proven efficacy and an established tolerability 
profile in schizophrenia. The once-daily extended-release formulation (quetiapine XR) offers 
a simplified dosing regimen and titration schedule. Short-term clinical studies have shown that 
quetiapine XR (400–800 mg/d) is efficacious in the acute treatment of schizophrenia, while a 
long-term study has shown that quetiapine XR was significantly more effective than placebo 
at preventing relapse. Furthermore, an investigation in which stable patients switched from the 
immediate-release formulation (quetiapine IR) to quetiapine XR showed that quetiapine XR is 
generally well tolerated and has no loss of efficacy compared with quetiapine IR. In patients who 
experienced insufficient efficacy or poor tolerability on their previous antipsychotic, switching 
to quetiapine XR significantly improved efficacy compared with the previous treatment. In 
  conclusion, quetiapine XR is an effective and generally well tolerated treatment for schizophrenia. 
Furthermore, once-daily dosing may improve patient adherence, which may impact positively 
on patient outcomes.
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Introduction
Schizophrenia is a debilitating and isolating disease imposing a significant burden on 
the lives of those affected, and its effective, and particularly long-term, management 
remains a significant clinical challenge. Enduring symptomatic improvement is required 
to improve and maintain quality of life and day-to-day functioning, and to achieve 
reasonable patient expectations of daily living. To achieve these goals, successful 
pharmacological treatment should be individualized and should provide a good balance 
between efficacy and tolerability.1
Whilst the responsibility of optimizing treatment lies in the hands of the physi-
cian, the extent of any clinical benefit is severely compromised if the patient does 
not take medication as prescribed. For patients with schizophrenia, nonadherence or 
partial adherence to medication is common, with almost half of patients estimated to 
be taking their medication as prescribed less than 75% of the time.2 Furthermore, the 
number of patients adherent to medication has been shown to decrease proportion-
ally over time.3 Partial adherence to antipsychotic medication can lead to significant Neuropsychiatric Disease and Treatment 2011:7 submit your manuscript | www.dovepress.com
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problems when trying to evaluate medication efficacy, 
  optimize dose, and determine any requirement for concomi-
tant medication.4
Moreover, partial adherence or nonadherence has seri-
ous clinical consequences including worsening of psychotic 
symptoms, increased (self-) aggression, suboptimal long-
term outcome, and perhaps most significantly, increased 
risk of relapse and hospitalization.5–8 Schizophrenic relapse 
has been shown to be associated with poor prognosis and 
increased health care costs.9,10
In addition to the clinical impact, nonadherence is asso-
ciated with a considerable financial burden. A retrospective 
review of Medicaid 2001–2003 data describing patients with 
schizophrenia suggested that elimination of nonadherence 
leading to hospitalization (which accounted for 36.6% of acute 
care inpatient admissions) could result in a 12% reduction 
in acute care admissions and a 13% reduction in the   number 
of inpatient treatment days.   Altogether this was   estimated 
to realize savings of approximately US$106   million in the 
United States alone.11
A wide variety of factors influence adherence to medica-
tion, including patient- (eg, age, attitude toward illness and 
treatment), illness- (eg, patient insight and comorbidity), 
physician- (eg, provision of information and the physician–
patient relationship), and treatment-related issues.2,12 In an 
investigation into the reasons for poor adherence, 153 patients 
with schizophrenia were asked to identify factors they 
considered to be barriers to medication adherence. The 
mean number of barriers identified per patient was 1.8; the 
barriers identified are presented in Figure 1.13 The most 
commonly reported barriers included social stigma associated 
with psychiatric illness, adverse events (AEs), and memory 
problems.
Separately, it has been shown that patients with a negative 
attitude toward treatment, which can be a direct result of 
poor tolerability, are more likely to be nonadherent to their 
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Figure 1 Reported barriers to medication adherence in patients with schizophrenia.
Hudson TJ, Owen RR, Thrush CR, et al. A pilot study of barriers to medication adherence in schizophrenia. J Clin Psychiatry. 2004;65(2):211–216.13 Copyright © 2004 
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antipsychotic medication.14 Patients with schizophrenia have 
been demonstrated to have more concern, more negative 
  opinions, and less feeling of necessity than patients with 
  bipolar disorder.2,15 A lack of efficacy can also result in 
patients   discontinuing their medication.16–18 Also, poor 
insight, previous nonadherence, substance abuse, shorter 
illness duration, inadequate aftercare, and a poorer patient–
physician relationship have all been shown to be consistently 
associated with nonadherence, whereas factors including 
education level, neurocognitive impairment, severity of 
psychotic symptoms, and the presence of mood symptoms 
were not consistently associated with lack of adherence.2
Atypical antipsychotics are currently considered to be 
first-line treatments for schizophrenia.19,20 A key   advantage 
of the atypical antipsychotics over the conventional 
antipsychotics is that, as a class, they are better tolerated, 
in particular with regard to their reduced propensity for 
extrapyramidal symptoms (EPSs).21 However, atypical 
antipsychotics have been associated with weight gain and 
metabolic AEs, with the incidence of these events varying 
according to the drug studied.22,23
Immediate-release quetiapine fumarate (quetiapine IR) is 
a well established, effective, atypical antipsychotic treatment 
for patients with schizophrenia, having shown efficacy across 
a broad range of symptoms (positive, negative, cognitive, and 
affective).24–27 The recommended initial dose of quetiapine IR 
is 25 mg twice daily, with increases in total daily dose of 
25–50 mg divided into two or three daily doses on days 2 and 
3, as tolerated, to a daily dose range of 300–400 mg, given 
in two or three doses, by day 4. When dose adjustment is 
required, increases or decreases of 25–50 mg divided twice 
daily are recommended.28 It has also been reported that a 
more rapid titration can provide safe and effective treatment.24 
Extended-release quetiapine fumarate (quetiapine XR) is   
a once-daily formulation, developed to provide patients and 
physicians with a more convenient dosing regimen and a 
simpler dose initiation so patients can reach the recommended 
therapeutic dose range (400–800 mg/d) by day 2–3 of 
treatment.29
Quetiapine XR is effective and generally well tolerated 
in patients with schizophrenia or bipolar disorder,30,31 and 
is currently approved for the treatment of schizophrenia, 
acute manic and mixed episodes associated with bipolar 
I   disorder, and acute treatment of depressive episodes 
associated with bipolar disorder in the United States32 and 
several other countries around the world. Beyond acute treat-
ment, quetiapine XR is approved for relapse prevention in 
patients with stable schizophrenia.33 Quetiapine XR is also 
approved for maintenance treatment of bipolar I disorder 
as adjunctive therapy to lithium or divalproex in the United 
States32 and for recurrence prevention in bipolar disorder as 
monotherapy in the European Union.34 Several studies have 
demonstrated the efficacy of quetiapine XR in major depres-
sive disorder (MDD)35–39 and generalized anxiety disorder,40–43 
and quetiapine XR has recently been approved in the United 
States and the European Union as adjunctive treatment to 
antidepressants in adults with MDD.44,45
This review will examine the pharmacokinetics, 
pharmacology, efficacy, and tolerability of quetiapine XR 
in patients with schizophrenia and will discuss the potential 
clinical benefits of this new formulation in the treatment of 
schizophrenia.
Pharmacokinetic overview  
of quetiapine XR
The quetiapine XR formulation is based on gel matrix 
technology using a soluble polymer to control the release 
of quetiapine fumarate from the tablet. When hypromellose 
comes into contact with water, the polymer swells and forms 
a gelatinous layer around the tablet that helps control the 
release of quetiapine from the tablet core. Quetiapine release 
is predominantly erosion controlled and occurs gradually, 
rather than the rapid release into the blood stream seen with 
the IR formulation. Consequently, quetiapine XR provides 
comparable bioavailability, compared with the existing 
IR formulation. Moreover, the time to reach peak plasma 
concentration (Cmax) is prolonged, and plasma levels are 
sustained at higher levels for a longer period of time. As 
a result of these properties, the quetiapine XR formulation 
allows less frequent dosing to maintain therapeutic drug 
concentrations.46
Pharmacokinetic profile
Quetiapine XR and IR each have a linear pharmacokinetic 
profile and a half-life of approximately 7 hours when 
administered at doses within the recommended therapeutic 
range.47,48 An open-label, randomized, crossover study in 
patients with schizophrenia, schizoaffective disorder, or 
bipolar disorder reported equivalent areas under the 24-hour 
quetiapine plasma concentration curve with the XR and IR 
formulations.46 Once-daily dosing of quetiapine XR 300 mg 
gave rise to mean Cmax approximately 13% lower than those 
observed with twice-daily dosing of quetiapine IR 150 mg 
and took longer to reach Cmax (5 hours versus 2 hours) 
(Figure 2).46 Comparison of once-daily dosing of the XR and 
IR formulations (both 300 mg) found a geometric mean ratio Neuropsychiatric Disease and Treatment 2011:7 submit your manuscript | www.dovepress.com
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for Cmax of 0.55 (90% confidence interval [CI] 0.49–0.60) 
and for the area under the plasma concentration–time 
curve from time 0 to 11 hours post-dose of 0.89 (90% CI 
0.82–0.96); time to Cmax (Tmax) was 5 hours and 2 hours, 
respectively.49 The extended Tmax with the XR formulation 
means that evening dosing of quetiapine XR ensures 
lower plasma levels of quetiapine during the day. It is 
recommended that quetiapine XR not be taken with food 
because despite intake of a light meal (300 calories, no fat) 
having no significant effect on quetiapine XR steady-state 
pharmacokinetics,50 consumption of a high-fat meal increases 
quetiapine XR bioavailability.29 The recommendation that 
once-daily quetiapine XR be administered in the evening 
should minimize the clinical relevance of any impact of food 
consumption on quetiapine XR bioavailability.
Mechanism of action of quetiapine
Both quetiapine and its relatively recently characterized major 
active human metabolite, norquetiapine (N-desalkylquetiap-
ine), have moderate affinity for dopamine D2 receptors, and 
are potent antagonists of serotonin 5-hydroxytryptamine 
type 2A (5-HT2A) receptors.51 Occupancy of D2 receptors is 
thought to be the primary route by which antipsychotic agents 
mediate their effect; however, it is also considered to be the 
main mechanism responsible for inducing EPSs. The reduced 
incidence of EPSs with atypical antipsychotics, including 
quetiapine, compared with conventional antipsychotics is 
believed to be a result of their rapid dissociation from D2 
receptors52 and higher affinity for 5-HT2A receptors.53 Positron 
emission tomography (PET) studies have shown low to mod-
erate D2 occupancy by quetiapine throughout the therapeutic 
dose range for schizophrenia, 400–800 mg/d, due to its rapid 
dissociation from the receptor.54,55
The established pharmacological profile of quetiapine 
does not adequately explain the antidepressant and mood-
stabilizing properties of quetiapine IR and quetiapine XR 
observed in clinical trials. Whilst questions remain, the com-
bined effects of quetiapine and norquetiapine may provide an 
explanation for the observed clinical profile. For example, 
norquetiapine has a moderate affinity for the 5-HT2C receptor 
(antagonist) and is a partial agonist for the 5-HT1H receptor, 
which together with antagonism of the 5-HT2A receptor, may 
be associated with cognitive and mood enhancing/stabilizing 
properties.56
In addition to its affinity for D2 and 5-HT2 receptors, 
norquetiapine is also a potent inhibitor of the norepinephrine 
transporter (NET). PET imaging in nonhuman primates has 
demonstrated quetiapine and norquetiapine occupancy at D2, 
5-HT2A, and norquetiapine occupancy at the NET at clinically 
relevant plasma levels.57 The clinical relevance of these find-
ings has been supported by PET studies demonstrating NET 
occupancy by norquetiapine in humans. Also, quetiapine and 
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Figure 2 Mean plasma quetiapine concentrations (and standard errors of the mean) measured over a 24-hour dosing interval for quetiapine IR and quetiapine XR. 
Reproduced with permission.46 Figueroa C, Brecher M, Hamer-Maansson JE, Winter H. Pharmacokinetic profiles of extended release quetiapine fumarate compared with 
quetiapine immediate release. Prog Neuropsychopharmacol Biol Psychiatry. 2009;33(2):199–204.
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norquetiapine bind to the 5-HT1 A and 5-HT1C receptors with 
a moderate to high affinity, which is similar to established 
antidepressants.58 The receptor-binding profile of quetiapine 
and norquetiapine may explain its efficacy demonstrated 
across a number of different psychiatric disorders.58
A further PET study, which compared the D2 receptor 
binding at peak and trough plasma concentration in patients 
with schizophrenia, found that quetiapine IR (dosed twice 
daily) and quetiapine XR (dosed once daily) 300, 600, and 
800 mg/d demonstrated comparable central D2 receptor 
occupancy for both formulations.59 PET scans in a study in 
healthy volunteers showed that D2 occupancy at maximum 
quetiapine plasma concentration was consistently lower in 
individuals treated with quetiapine XR 300 mg once daily 
compared with those receiving quetiapine IR 300 mg once 
daily (32% versus 49%).55 These combined pharmacological 
properties of quetiapine have not been described for any other 
psychotropic drug.
Norquetiapine and quetiapine have also shown high 
affinity for the histaminergic H1 receptor, and moderate 
affinity for the adrenergic receptor α1B. While quetiapine has 
low affinity for muscarinic receptors, norquetiapine acts as 
an antagonist at the muscarinic receptors M1, M3, and M5. 
These mechanisms may contribute to the side-effect profile 
of quetiapine.58
Additionally, in common with other atypical antipsy-
chotics,60 evidence from animal models suggests that 
quetiapine may have neuroprotective effects, mediated 
through its modulation of the expression of neurotrophic 
factors including brain-derived neurotrophic factor.61,62
Clinical efficacy studies
Several clinical trials have been conducted to evaluate the 
efficacy of quetiapine XR in patients with schizophrenia 
over both the short and long term. In addition, the feasibility 
of switching from quetiapine IR or other antipsychotic 
medication to quetiapine XR has been investigated 
(Table 1).31,63–67
Acute trials
To date, three 6-week trials to investigate the efficacy and 
tolerability of quetiapine XR and quetiapine IR versus 
placebo for the treatment of acute schizophrenia have been 
conducted. In all trials, male or female patients were aged 
18–65 years, and with a Diagnostic and Statistical Manual 
of Mental Disorders, 4th Edition (DSM-IV) diagnosis of 
schizophrenia. Patients were excluded if they had a DSM-IV 
diagnosis of any condition other than schizophrenia.
Quetiapine XR has demonstrated efficacy in the treatment 
of acute schizophrenia in a randomized, double-blind, 
placebo-controlled trial (D1444C00132).64 This was an 
international study conducted in 39 centers in Europe, Asia, 
and South Africa. Patients (n = 588) were randomized to 
receive fixed-dose quetiapine XR 400, 600, or 800 mg/d 
(once daily in the evening), quetiapine IR 400 mg/d (200 mg 
twice daily), or dual-matched placebo (ie, patients receiving 
quetiapine XR received placebo in the morning and active 
treatment in the evening). Quetiapine XR was initiated at 
300 mg/d and rapidly titrated, with target doses reached 
by day 2 (400 and 600 mg) or day 3 (800 mg) (Table 2).64 
The primary efficacy endpoint was change from baseline to 
week 6 in Positive and Negative Syndrome Scale (PANSS) 
total score. Last observation carried forward analysis of the 
modified intention-to-treat population showed that compared 
with placebo the change in PANSS total score was statisti-
cally significant for all four active treatments (Figure 3),64 
with a post-hoc analysis demonstrating a dose response 
for quetiapine XR. Analysis of several secondary efficacy 
variables similarly showed a significant improvement with 
quetiapine XR and quetiapine IR compared with placebo. 
At week 6, changes from baseline in PANSS positive and 
general psychopathology subscales and PANSS aggression/
hostility cluster were statistically significant for all quetiapine 
doses compared with placebo; decreases in the PANSS nega-
tive subscale and depression cluster scores were significant 
for quetiapine XR 600 and 800 mg/d.64,68 Furthermore, both 
PANSS and Clinical Global Impression–Improvement scale 
(CGI-I) response rates at week 6 were significantly greater 
with all active treatments compared with placebo and CGI-
Severity of Illness (CGI-S) score was statistically significant 
for quetiapine XR 600 and 800 mg/d and quetiapine IR 
versus placebo.64
A similarly designed study (D1444C00133; n = 565), 
conducted in the United States, failed to demonstrate a 
  significant improvement in efficacy for quetiapine XR (400, 
600, or 800 mg/d) or quetiapine IR (800 mg/d) compared with 
placebo.67 This outcome was in contrast to the results of study 
D1444C00132, and surprising given the proven efficacy of 
quetiapine IR in this patient group. There are several   possible 
reasons for the failure of an active treatment to separate 
from placebo in a clinical study. In this case, two probable 
causes may be: the lack of requirement for   hospitalization 
and other factors biasing towards the selection of a less 
acutely ill patient population, and geographic differences 
from study 132 resulting in key differences between the 
two study populations. A post-hoc analysis of the primary Neuropsychiatric Disease and Treatment 2011:7 submit your manuscript | www.dovepress.com
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efficacy variable (change in PANSS total score at week 6) 
revealed that there was a significant separation from placebo 
in patients who were markedly ill at baseline (CGI-S $ 5) for 
the quetiapine XR 600 and 800 mg/d groups. In contrast, in 
patients classified as moderately ill at baseline (CGI-S , 5), 
there was a rapid and sustained placebo response and no 
active treatment group separated from placebo.
A further 6-week, randomized, double-blind, placebo-
controlled trial (5077IL/0041) investigated the efficacy and 
tolerability of quetiapine XR (300, 600, or 800 mg/d) and 
quetiapine IR (300 and 600 mg/d), in 532 patients with 
acute schizophrenia who were hospitalized for at least the 
first 10 days of the study. Of the active treatments, only 
quetiapine XR 600 mg/d demonstrated significant improve-
ments in the primary outcome measure (change in PANSS 
score from baseline to week 6).65 There was no significant 
improvement in PANSS total score over the duration of the 
study with quetiapine IR (300 or 600 mg/d), a finding that 
contrasts with the documented efficacy of quetiapine IR in 
patients with schizophrenia. For the secondary outcome 
Table 1 Summary of published efficacy and tolerability studies of quetiapine XR in adult patients with schizophrenia
Study identifier Study design Study efficacy outcomes Reference
D1444C00132 6-week, randomized, double-blind, placebo-
controlled study. 
Patients were randomized to receive quetiapine XR 
400, 600, or 800 mg/d, quetiapine IR  
400 mg/d, or placebo.
Significant improvements in PANSS total score, 
PANSS, and CGI-I response rates with all active 
treatments versus placebo.
Kahn et al64
D1444C00133 6-week, randomized, double-blind,  
placebo-controlled study. 
Patients were randomized to receive quetiapine XR 
400, 600, or 800 mg/d, quetiapine IR 800 mg/d,  
or placebo.
Greater numeric improvements in PANSS total 
score were seen for quetiapine XR (all doses) 
and quetiapine IR versus placebo at week 6; the 
differences were not statistically significant. 
Secondary efficacy endpoint results did not 
significantly separate from placebo. 
A post-hoc analysis of the primary efficacy  
variable (change in PANSS total score at week 6) 
revealed that there was a significant separation  
from placebo in patients who were markedly ill  
at baseline (CGI-S $ 5) for the quetiapine XR  
600 and 800 mg/d groups.
Cutler et al67
5077IL/0041 6-week, randomized, double-blind, placebo-
controlled study. 
Patients were randomized to receive quetiapine XR 
400, 600, or 800 mg/d, quetiapine IR 300 or  
600 mg/d, or placebo.
Statistically significant improvement in PANSS  
total score versus placebo recorded only for 
quetiapine XR 600 mg/d. 
Numerical, but not significant, improvements  
in other efficacy measures.
Lindenmayer et al65
D1444C00004 Long-term, randomized, double-blind, placebo-
controlled study. 
Patients received quetiapine XR 400–800 mg/d 
(flexible dosing) for 16 weeks; clinically stable 
patients were randomized to quetiapine XR  
400–800 mg/d (flexible dosing) or placebo.
Study terminated early because first interim  
analysis showed significant difference between 
treatment groups. 
Quetiapine XR significantly prolonged time  
to relapse versus placebo.
Peuskens et al31
D1444C00146 6-week, double-blind, randomized, parallel group, 
fixed-dose study with a 4-week run-in period. 
Patients received quetiapine IR 400, 600, or  
800 mg/d during the run-in period; clinically  
stable patients were randomized to receive 
quetiapine XR or quetiapine IR at the same  
daily dose received during run-in.
Efficacy maintained. 
For the per-protocol population, quetiapine XR  
was noninferior to quetiapine IR in an analysis  
of the proportion of patients who discontinued  
due to lack of efficacy, or whose PANSS total  
score increased by $ 20% from randomization.
Moller et al66
D1444C00147 12-week, open-label study in patients with 
schizophrenia who were experiencing  
inadequate efficacy or tolerability with their  
ongoing antipsychotic medication. 
Patients were switched to quetiapine XR  
400–800 mg/d (flexible-dosing) during a  
4-day cross-titration period.
Patients switched to quetiapine XR experienced  
a significant clinical benefit (improvements in  
CGI-I and PANSS total scores; P , 0.0001).
Ganesan et al63
Abbreviations: CGI-I, Clinical Global Impression-Improvement; IR, immediate release; PANSS, Positive and Negative Syndrome Scale; XR, extended release.Neuropsychiatric Disease and Treatment 2011:7 submit your manuscript | www.dovepress.com
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  measures evaluated, quetiapine XR and quetiapine IR pro-
vided a numerical advantage over placebo; however, signifi-
cance was not achieved.
The author of this study was unable to identify any one 
factor responsible for the unexpected outcome of the inves-
tigation, and a combination of numerous factors including a 
high attrition rate and short study duration were considered to 
be contributory.65 It should be noted that this study included a 
slower dose titration with quetiapine XR, with the 600 mg/d 
dose not reached until day 5, and 800 mg/d not reached until 
day 8. It is possible that this may have resulted in a lower 
plasma concentration of quetiapine towards the beginning 
of the trial resulting in attenuated efficacy or premature 
  discontinuation due to perceived lack of efficacy.
Switching studies
With the introduction of any novel antipsychotic, it is 
important to evaluate the possibility of switching to the drug 
from other antipsychotic formulations in order to establish 
whether efficacy is maintained and to confirm that there are 
no adverse effects on tolerability.
The viability of switching from quetiapine IR to XR has 
been investigated in a double-blind, double-dummy study 
(D1444C00146) in outpatients with schizophrenia.66 Patients 
who were clinically stable (CGI-S score # 3) received a 
stable dose of quetiapine IR (400, 600, or 800 mg/d) for 
the 4-week run-in period. Patients who remained stable 
were then randomized to continue receiving the same dose 
of quetiapine IR (n = 166) or to switch to the same total 
daily dose of quetiapine XR (n = 331). There was no cross-
titration period, and the switch was achieved in a single day. 
Analysis of the proportion of patients who discontinued due 
to lack of efficacy, or whose PANSS total score increased 
by $ 20% from randomization, demonstrated noninferiority 
of quetiapine XR compared with quetiapine IR for the 
per-protocol population. The results of secondary efficacy 
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Figure 3 Change in PANSS total score from baseline to week 6 (MITT, LOCF).
Notes: *P , 0.05; **P , 0.01; ***P , 0.001 versus placebo.
Kahn RS, Schulz SC, Palazov VD, et al. Efficacy and tolerability of once-daily extended release quetiapine fumarate in acute schizophrenia: a randomized, double-blind, placebo-
controlled study. J Clin Psychiatry. 2007;68(6):832–842.64 Copyright © 2007 Physicians Postgraduate Press. Reprinted by permission.
Abbreviations:  IR,  immediate  release;  LOCF,  last  observation  carried  forward;  MITT,  modified  intention-to-treat;  PANSS,  Positive  and  Negative  Syndrome  Scale; 
XR, extended release.
Table 2 Dose initiation schedule for quetiapine XR
Target dose Day 1 Day 2 Day 3 Day 4 Day 5 Days 6–42
Quetiapine XR 400 mg 300 mg 400 mg 400 mg 400 mg 400 mg 400 mg
Quetiapine XR 600 mg 300 mg 600 mg 600 mg 600 mg 600 mg 600 mg
Quetiapine XR 800 mg 300 mg 600 mg 800 mg 800 mg 800 mg 800 mg
Quetiapine IR 400 mg 50 mg 100 mg 200 mg 300 mg 400 mg 400 mg
Abbreviations: IR, immediate release; XR, extended release.Neuropsychiatric Disease and Treatment 2011:7 submit your manuscript | www.dovepress.com
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variables (including mean change in PANSS total score and 
proportion of patients with a CGI-I score # 4 at study end) 
were similar for quetiapine IR and XR, demonstrating that 
efficacy was maintained following the switch.
A further 12-week, open-label study (D1444C00147) 
investigated the potential for clinical benefit of switching to 
quetiapine XR from conventional or atypical antipsychotic 
therapy amongst in- or outpatients (n = 477) with schizo-
phrenia experiencing suboptimal efficacy or tolerability with 
their existing treatment.63 Switching to quetiapine XR was 
achieved during a 4-day cross-titration period, during which 
the dosage of current treatment was reduced to zero by day 4, 
and patients received 300 mg quetiapine XR on the evening 
of day 1, 600 mg on day 2, and were then flexibly dosed 
(  400–800 mg/d) from day 3 onwards. The primary endpoint 
was the percentage of patients achieving clinical benefit, 
defined as an improvement in CGI-Clinical Benefit score at 
week 12. A significant percentage of patients (62.8%) expe-
rienced a clinical benefit after switching to quetiapine XR; 
subgroup analysis showed that clinical benefit was experienced 
by 59.8% of patients switching due to insufficient efficacy and 
68.6% of patients switching due to insufficient tolerability 
(Figure 4).63   Improvements in the efficacy measures CGI-S (not 
significant), CGI-I, and PANSS total scores (both significant) 
were recorded following switching to quetiapine XR.63
Relapse prevention
As schizophrenia is a chronic condition, it is critical that 
new treatments maintain efficacy and are well tolerated over 
the long term. Furthermore, prevention of relapse remains 
a main objective of antipsychotic treatment and one that is 
often not met.69
A long-term, randomized, double-blind, placebo-
  controlled study (D1444C00004) investigated the effective-
ness of quetiapine XR at preventing relapse in patients with 
schizophrenia.31 Clinically stable patients (n = 327) were 
switched from their current antipsychotic to open-label, 
flexible-dose quetiapine XR (400–800 mg/d) in a 4-day 
cross-titration period, which was followed by a 16-week 
stabilization phase. Those patients who were clinically 
stable at the end of the open-label phase were random-
ized to continue receiving flexible-dose quetiapine XR 
(400–800 mg/d) or placebo. Treatment was planned to last 
for 1 year, or until relapse. The study was terminated early 
after a   pre-planned interim analysis showed that significantly 
more patients receiving placebo were suffering relapse com-
pared with patients receiving quetiapine XR (Figure 5).31 
The rate of relapse in the quetiapine XR group was low, and 
  consequently it was not possible to calculate a median time 
to relapse. In the intention-to-treat population, the risk of 
relapse was reduced by 87% (hazard ratio 0.13; P , 0.0001) 
for patients who received quetiapine XR compared with 
placebo, and the estimated time at which 80% of patients 
remained relapse-free was 6.3 months for quetiapine XR 
compared with 1.2 months for placebo.
Consensus-based criteria for definition of symptomatic 
remission in schizophrenia were proposed in 2005.70 The 
working group defined symptomatic remission as a state 
in which patients have experienced an improvement in 
core signs and symptoms to the extent that any remain-
ing symptom  atology is of such low intensity that it no 
longer interferes significantly with behavior. Specific core 
symptoms were selected to map the three dimensions of 
psychopathology and the five criteria for schizophrenia 
specified in DSM-IV . Remission was defined by the working 
group as having a severity score of mild or less for the core 
symptoms rated in one of the following scales: PANSS (item 
scores # 3); Brief Psychiatric Rating Scale (item scores # 3); 
Scale for Assessment of Positive Symptoms and Scale for 
Assessment of Negative Symptoms (item scores # 2) for a 
period of at least 6 months during which symptom severity 
must be maintained. Cross-sectional remission is defined as 
a symptomatic remission at a specific timepoint and does not 
require fulfillment of the 6-month criteria.70,71
Using these cross-sectional remission criteria, a post-
hoc analysis of the results of the previously described 
relapse prevention study31 was conducted. Following the 
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open-label phase (16-weeks quetiapine XR 400–800 mg/d), 
at the point of randomization into the flexible dosing 
phase, 96.6% of patients who had been in cross-sectional 
remission at   enrolment were still in cross-sectional remis-
sion;   furthermore, 76.6% of patients not in cross-sectional 
remission at enrolment were in cross-sectional remission at 
randomization.72 Analysis of those patients with sustained 
remission (patients who fulfilled remission criteria at ran-
domization and all previous visits), showed that placebo 
was associated with a significantly shorter time to loss of 
remission compared with quetiapine XR.
Safety and tolerability
Quetiapine XR: overview of tolerability
In a pooled analysis of the previously described acute   studies 
(D1444C00132, D1444C00133, and 5077IL/0041), the inci-
dences of AEs were similar in all three treatment groups: que-
tiapine XR 69.5%, quetiapine IR 72.5%, and placebo 61.4%. 
The rates of serious AEs were low, with the highest incidence 
(6.1%) occurring in the quetiapine IR 800 mg/d group and 
the lowest (1.1%) occurring in the quetiapine IR 300 mg/d 
group; the incidence of serious AEs in the quetiapine IR, 
quetiapine XR, and placebo groups was 3.9%, 4.4%, and 
4.4%, respectively.73
The profile of common AEs from this pooled analysis is 
shown in Table 373 and was comparable in the quetiapine XR 
and quetiapine IR groups. The most common AEs occurring 
with quetiapine XR in these acute studies were sedation, dry 
mouth, somnolence, dizziness, and headache.73
In a long-term, randomized study of quetiapine XR in 
clinically stable patients with schizophrenia (D1444C00004, 
described above), a total of 49.8% of patients experienced AEs 
in the stabilization phase when all patients were treated with 
open-label quetiapine XR. In the double-blind randomized phase 
of the study, a comparable percentage of patients reported AEs 
in the quetiapine XR (31.9%) and placebo (40.8%) groups, of 
which 18.1% and 21.4%, respectively, were considered treat-
ment related.31 The majority of AEs reported throughout the 
study were mild to moderate in severity, and there were only two 
serious AEs in the study, both in placebo-treated patients (one 
death due to suicide and one moderate “peritonsillar abscess”). 
Furthermore, there were low levels of withdrawals due to AEs 
during the randomized phase, with one patient withdrawing from 
each of the quetiapine XR and placebo groups.
Rapid dose initiation
A post-hoc analysis of pooled data from two acute   studies 
(D1444C00132 and D1444C00133, described above) 
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investigated the tolerability of quetiapine XR during 
rapid dose initiation (in these studies target doses of 
quetiapine XR were reached by day 2 [400 and 600 mg/d] 
and day 3 [800 mg/d]).73 During the first week of treatment, 
the   incidence of AEs was similar in the quetiapine XR (43%) 
and quetiapine IR (42%) groups, compared with 32% in 
the placebo group. The most commonly reported AEs in 
this period were somnolence, sedation, dry mouth, and 
dizziness in the quetiapine XR and quetiapine IR groups. 
The incidence of serious AEs was low in all treatment groups 
(1.2% quetiapine XR, 1.3% quetiapine IR, 0.4% placebo).   
A total of 14 patients discontinued from the study during the 
first week; 10 (1.5%) in the quetiapine XR groups, and two 
in the quetiapine IR (0.8%) and placebo (0.9%) groups.
Orthostatic hypotension, dizziness, and syncope are of 
specific concern during rapid titration of quetiapine.74 In 
the post-hoc analysis, the incidence of these events was 
low during the first week of treatment, supporting rapid 
initiation.73
Somnolence
The incidence of AEs potentially associated with somnolence 
in short-term trials of quetiapine XR was consistent with 
the known safety profile for quetiapine IR: quetiapine XR, 
25.0%; quetiapine IR, 29.5%; and placebo, 10.3%. Events 
generally occurred early in treatment (median time to onset: 
quetiapine XR, 3.0 days; quetiapine IR, 2.0 days; placebo, 
4.0 days) and were mild in intensity.73 Similarly, in the long-
term study,31 the majority of AEs potentially associated with 
somnolence occurred during the first 2 weeks after enrolment. 
Overall, 19% of patients experienced somnolence during the 
16-week open-label phase, when all patients were receiving 
quetiapine XR, and 14.4% experienced this AE during the 
first 14 days. The incidence of somnolence was reduced at 
randomization (2.1%), following 16-weeks of quetiapine XR 
400–800 mg/d, and during the randomized phase two patients 
receiving placebo (1.9%) and none receiving quetiapine XR 
reported somnolence.
EPS
In an analysis of pooled data from three acute studies, the 
incidences of AEs potentially associated with EPSs were: 
quetiapine XR, 7.5%; quetiapine IR, 7.7%; and placebo 
4.7%.73 The most common EPS-associated AEs were tremor, 
akathisia, and restlessness; no individual AE occurred with a 
frequency .3% in either the quetiapine XR or quetiapine IR 
group. The majority of AEs related to EPSs were of mild or 
moderate severity.
In a long-term study, the incidence and severity of EPSs 
were assessed using the Simpson–Angus Scale (SAS) and 
Barnes Akathisia Rating Scale (BARS), monitoring of 
anticholinergic medication use, and AE reporting. Mean 
change in SAS and BARS scores from baseline to the end 
of treatment were −0.08 and −0.02, respectively, in the 
quetiapine XR groups and −0.25 and −0.01, respectively, in 
the placebo group. Anticholinergic use was low throughout, 
with no indication of an increase in use.31
Prolactin
Prolactin levels decreased in all treatment groups during acute 
studies; the mean decrease observed with quetiapine XR 
(−12.96 ng/mL) was comparable with both quetiapine IR 
(−13.33 ng/mL) and placebo (−13.69 ng/mL).73 The incidence 
of AEs potentially associated with prolactin was also similar 
across the study groups.
Weight and metabolic effects
Pooled data from the three acute studies showed a mean 
weight gain of 1.77 kg in the quetiapine XR group, 2.19 kg 
in the quetiapine IR group, and 0.26 kg in the placebo group; 
there was no apparent dose–response relationship.73 A greater 
percentage of patients in the quetiapine XR and quetiapine IR 
groups reported a weight increase $ 7% compared with the 
placebo group (13.7%, 19.5%, and 6.7%, respectively).73
During the stabilization phase of the long-term study 
(16 weeks), patients experienced a mean weight increase 
of 0.89 kg, and 8.1% of patients experienced a weight 
increase $ 7%. Following randomization, patients in the 
quetiapine XR group experienced a further mean weight 
gain of 0.46 kg, while those receiving placebo recorded a 
mean decrease of −0.68 kg. Weight increase $ 7% from 
randomization to study end (mean duration 120 days) 
occurred in 5.4% of patients receiving quetiapine XR and 
1.0% of patients receiving placebo. Over the course of the 
study patients receiving quetiapine XR experienced a mean 
weight gain of 1.06 kg.31
In the acute studies, mean changes from randomization in 
fasting glucose levels were +0.12, +0.27, and −0.01 mmol/L 
in the quetiapine XR, quetiapine IR, and placebo groups, 
respectively.73 A clinically important shift in fasting glucose 
to $ 7 mmol/L was experienced by 8.7%, 6.7%, and 5.9% 
of patients in the quetiapine XR, quetiapine IR, and placebo 
groups, respectively.73 In the long-term study, mean change 
from randomization in fasting glucose levels (quetiapine XR, 
+0.34 mmol/L; placebo, +0.19 mmol/L) was similar to that 
seen in the short-term studies (quetiapine XR difference Neuropsychiatric Disease and Treatment 2011:7 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
560
Peuskens
versus placebo: +0.15 and +0.13 mmol/L, respectively), 
with no meaningful difference between treatment groups. 
During the stabilization phase, mean fasting glucose levels 
increased by 0.05 mmol/L; following randomization levels 
increased by 0.34 mmol/L in the quetiapine XR group and 
0.19 mmol/L in the placebo group. Clinically significant 
shifts (to $ 7 mmol/L) from baseline to end of treatment 
were recorded in 4.1% of patients receiving quetiapine XR 
and 8.0% of patients receiving placebo.31
Analysis of pooled data from acute studies quantified 
changes from randomization in fasting lipid parameters 
among the quetiapine XR, quetiapine IR, and placebo 
cohorts, respectively (+0.06, +0.15, and –0.06 mmol/L in low-
density lipoprotein [LDL]; −0.01, 0.00, and −0.02 mmol/L 
in high-density lipoprotein [HDL]; and +0.17, +0.38, 
and −0.11 mmol/L in triglycerides).73
Long-term respective changes from randomization 
in fasting lipid parameters among quetiapine XR- and 
placebo-treated patients were −0.01 and −0.28 mmol/L 
(LDL), +0.01 and +0.06 mmol/L (HDL), and −0.03 
and −0.23 mmol/L (triglycerides).31 Collectively, these 
data suggest that short- and long-term treatment with 
quetiapine XR does not lead to clinically meaningful 
changes in fasting lipid parameters.
Switching
The safety data from the switching study, which investigated 
the feasibility of switching from quetiapine IR to quetiapine XR 
at equivalent doses, indicated that the switch was not associ-
ated with any compromise in tolerability. Similar AE profiles 
were seen in patients who switched to quetiapine XR and those 
who remained on quetiapine IR; 38.7% and 35.5% of patients 
in the quetiapine XR and quetiapine IR groups, respectively, 
reported AEs. Slight increases in the incidence of some AEs 
were observed with quetiapine XR; however, the differences 
were small and may have been attributable to chance. The 
mean weight change was −0.02 kg for quetiapine XR and 
0.30 kg for quetiapine IR; weight increase $7% occurred 
in 1.5% of patients receiving quetiapine XR and 2.4% of 
patients receiving quetiapine IR. The two treatment groups 
were also comparable with regard to the recorded changes 
in laboratory values, which were small and similar in both 
groups.66
In patients who switched from their current medication, 
including conventional and atypical antipsychotics, 
quetiapine XR was generally well tolerated. The majority of 
AEs were mild to moderate in intensity, and the incidence 
of serious AEs and AEs leading to discontinuation was 
low: 4.4% and 8.0%, respectively. The percentage of 
patients experiencing an AE was slightly higher in patients 
who switched due to insufficient tolerability (75.3%) 
compared with patients who switched due to insufficient 
efficacy (68.6%). The AE profile and effect on vital signs 
and laboratory data were generally consistent with other 
studies of quetiapine XR. For all patients, the mean change 
in bodyweight was 1.0 kg; for those who switched from 
their previous antipsychotic due to weight gain, baseline 
bodyweight was higher and patients lost a mean weight of 
1.6 kg.63 In addition, in the long-term relapse prevention 
study,31 in which switching was achieved during a 4-day 
cross-titration period, the rate of withdrawal was low, 
providing supporting evidence that patients can be switched 
from their previous medication with little difficulty.
Tolerability of quetiapine IR  
versus XR: sedation
A randomized, double-blind, crossover study in healthy adult 
volunteers (D1443C00033) has been conducted to investigate 
the time course and intensity of sedation during dose initia-
tion of quetiapine XR and quetiapine IR.49 The self-reported 
level of sedation was recorded using a visual analog scale. 
At 1 hour on day 1 (primary endpoint), quetiapine XR was 
associated with a significantly reduced intensity of sedation 
compared with quetiapine IR. The level of sedation was 
lower with quetiapine XR for the first 7 hours post dosing, 
after which levels of sedation were comparable with both 
formulations.49
Patient-reported outcomes
In addition to efficacy and tolerability data, the previously 
described trial by Ganesan et al, in which switching from 
other antipsychotics to quetiapine XR was evaluated, also 
assessed patient-reported outcomes through recording of 
Personal Evaluation of Transitions in Treatment (PETiT) 
scores (a self-administered patient questionnaire compris-
ing 30 questions relating to perceived well being, adherence 
to treatment, tolerability, and satisfaction).63 At the end of 
the 12-week study, there was a significant improvement in 
PETiT total score in patients who switched to quetiapine XR; 
improvements were recorded irrespective of whether patients 
switched due to insufficient efficacy or tolerability.
It is important to consider the patients’ opinions of 
their medication; therefore, future trials evaluating the use 
of   quetiapine XR in patients with schizophrenia should 
incorporate patient-reported outcomes to provide further 
evidence for the benefits of the formulation.Neuropsychiatric Disease and Treatment 2011:7 submit your manuscript | www.dovepress.com
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Conclusion
While treatment options for schizophrenia have increased 
significantly over the past decade, the management of 
schizophrenia continues to represent a considerable clinical 
challenge. There are often differences between patients 
in terms of the pharmacokinetics and pharmacodynamics 
of different drugs. Furthermore, the relative importance 
of genetic and physiological factors in the development of 
schizophrenia is different for each patient. Consequently, the 
efficacy and tolerability of specific antipsychotic treatments 
differs from patient to patient, thus necessitating the ongoing 
development of new treatment options. Moreover, the 
chronic nature of schizophrenia means that treatment is not 
limited to an acute period but instead must extend over a 
long-term maintenance period, increasing the importance 
of having a wide variety of treatment options available to 
clinicians.
The efficacy of quetiapine IR for the treatment of 
schizophrenia is well established.24–26 Quetiapine XR was 
developed to aid clinicians and patients by offering an 
alternative treatment option with once-daily dosing and 
a simplified dose titration schedule. For patients with 
schizophrenia, rapid symptom relief is important, and 
consequently the ability to reach therapeutic doses rapidly 
is an advantage. The XR formulation enables the therapeutic 
dose range to be reached by day 2, with the highest dose of 
800 mg/d achievable by day 3 of treatment.
To be considered a viable treatment option, quetiapine XR 
must have comparable, or superior, efficacy and tolerability 
compared with the IR formulation. In several short- and 
long-term studies, quetiapine XR has demonstrated 
comparable efficacy with quetiapine IR in patients with 
schizophrenia.31,64,65,68 Furthermore, it has been shown that 
switching to quetiapine XR from quetiapine IR does not 
lead to any loss of efficacy, and switching to quetiapine XR 
from a different antipsychotic, due to insufficient efficacy or 
tolerability, results in improved efficacy.63,66
Studies of patient adherence to treatment in several 
chronic conditions has shown that patients are more 
adherent to once-daily medications, compared with more 
frequently dosed formulations.75 Nonadherence to medica-
tion is associated with poorer treatment outcomes, nega-
tively affecting remission and relapse rates, the need for 
rehospitalization, and the incidence of suicide attempts.8,76 
Furthermore, nonadherence is associated with significantly 
increased health care utilization and, consequently, costs.77 
The once-daily dosing schedule of quetiapine XR may help 
improve patient adherence to treatment, and as a result it has 
the potential to have a positive impact on patient outcomes 
and costs.
In common with many other atypical antipsychotics, 
quetiapine is associated with somnolence.78 The majority of 
instances of somnolence associated with either formulation 
of quetiapine appear to occur early in treatment and to be 
transient. In comparison with quetiapine IR, quetiapine XR 
has been shown to be associated with milder cases of   sedation 
and somnolence, particularly during dose initiation.49 The 
intensity of sedation is greatest in the first 7 hours after dos-
ing; therefore, the proposed once-daily evening dosing of 
quetiapine XR may minimize this potential side effect.
The evidence that successful treatment of schizophrenia 
must target nonpsychotic, as well as psychotic symptoms 
continues to increase. For example, the presence of depressive 
symptoms in patients with schizophrenia is associated 
with poorer treatment outcomes. In a recent large, 3-year, 
observational study, 39.4% of patients were considered 
to be depressed at enrolment (Montgomery-Åsberg 
Depression Rating Scale score $ 16). When compared with 
nondepressed patients, this group was more likely to require 
relapse-related mental health services, attempt suicide, have 
substance-related problems, report a poorer quality of life, 
and have reduced adherence to medication.79 Quetiapine XR 
has been demonstrated to improve depressive symptoms over 
6-weeks in patients with schizophrenia.64 In addition, the 
proven efficacy of quetiapine in bipolar depression30,80,81 and 
MDD37–39 together with its receptor-binding profile suggests 
that quetiapine may be an effective treatment for patients 
with schizophrenia and depressive symptoms.
A further treatment challenge in schizophrenia is 
relapse, which is common during the long-term treatment of 
schizophrenia. In one study, 25% of patients who achieved 
remission were estimated to relapse, with the risk of relapse 
continuing even after 3 years of remission.82 Quetiapine XR 
has been demonstrated to be effective in the prevention of 
relapse in clinically stable patients with schizophrenia31,72 
and thus offers a further treatment choice.
In conclusion, quetiapine XR represents an effective and 
generally well tolerated treatment for schizophrenia that is 
initiated rapidly and taken only once daily. The reduced dos-
ing frequency with quetiapine XR may increase adherence to 
treatment and, in turn, improve long-term outcomes.
Acknowledgments
The author thanks Dr Alex Mitchell, PhD, from Complete 
Medical Communications, who provided medical writing 
support funded by AstraZeneca.Neuropsychiatric Disease and Treatment 2011:7 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
562
Peuskens
Disclosure
The author reports no conflicts of interest in this work.
References
  1.  Weiden PJ, Preskorn SH, Fahnestock PA, Carpenter D, Ross R, Docherty 
JP. Translating the psychopharmacology of antipsychotics to individual-
ized treatment for severe mental illness: a Roadmap. J Clin Psychiatry. 
2007;68 Suppl 7:1–48.
  2.  Lacro JP, Dunn LB, Dolder CR, Leckband SG, Jeste DV . Prevalence 
of and risk factors for medication nonadherence in patients with schizo-
phrenia: a comprehensive review of recent literature. J Clin Psychiatry. 
2002;63(10):892–909.
  3.  Valenstein M, Ganoczy D, McCarthy JF, Myra KH, Lee TA, Blow FC. 
Antipsychotic adherence over time among patients receiving   treatment 
for schizophrenia: a retrospective review. J Clin Psychiatry. 2006; 
67(10):1542–1550.
  4.  Velligan DI, Lam F, Ereshefsky L, Miller AL. Psychopharmacology: 
perspectives on medication adherence and atypical antipsychotic 
medications. Psychiatr Serv. 2003;54(5):665–667.
  5.  Byerly MJ, Nakonezny PA, Lescouflair E. Antipsychotic medication 
adherence in schizophrenia. Psychiatr Clin North Am. 2007;30(3): 
437–452.
  6.  Gitlin M, Nuechterlein K, Subotnik KL, et al. Clinical outcome 
following neuroleptic discontinuation in patients with remitted   
recent-onset schizophrenia. Am J Psychiatry. 2001;158(11): 
1835–1842.
  7.  Ascher-Svanum H, Zhu B, Faries D, Lacro JP, Dolder CR. A prospective 
study of risk factors for nonadherence with antipsychotic medication 
in the treatment of schizophrenia. J Clin Psychiatry. 2006;67(7): 
1114–1123.
  8.  Leucht S, Heres S. Epidemiology, clinical consequences, and psycho-
social treatment of nonadherence in schizophrenia. J Clin Psychiatry. 
2006;67 Suppl 5:3–8.
  9.  Almond S, Knapp M, Francois C, Toumi M, Brugha T. Relapse 
in schizophrenia: costs, clinical outcomes and quality of life. Br J 
Psychiatry. 2004;184:346–351.
  10.  Wyatt RJ. Neuroleptics and the natural course of schizophrenia. 
Schizophr Bull. 1991;17(2):325–351.
  11.  Marcus SC, Olfson M. Outpatient antipsychotic treatment and inpatient 
costs of schizophrenia. Schizophr Bull. 2008;34(1):173–180.
  12.  Fleischhacker WW, Hofer A, Hummer M. Managing Schizophrenia: 
the compliance challenge. Current Medicine Group; 2007.
  13.  Hudson TJ, Owen RR, Thrush CR, et al. A pilot study of barriers to 
medication adherence in schizophrenia. J Clin Psychiatry. 2004;65(2): 
211–216.
  14.  Masand PS, Narasimhan M. Improving adherence to antipsychotic 
pharmacotherapy. Curr Clin Pharmacol. 2006;1(1):47–56.
  15.  Jonsdottir H, Friis S, Horne R, Pettersen KI, Reikvam A, Andreassen OA. 
Beliefs about medications: measurement and relationship to   adherence 
in patients with severe mental disorders. Acta Psychiatr Scand. 2009; 
119(1):78–84.
  16.  Tandon R, Marcus R, Stock E, et al. A prospective, multicenter, 
randomized, parallel-group, open-label study of aripiprazole in the man-
agement of patients with schizophrenia or schizoaffective   disorder in 
general psychiatric practice: Broad Effectiveness Trial with   Aripiprazole 
(BETA). Schizophr Res. 2006;84(1):77–89.
  17.  Kikkert MJ, Schene AH, Koeter MW, et al. Medication adherence in 
schizophrenia: exploring patients’, carers’ and professionals’ views. 
Schizophr Bull. 2006;32(4):786–794.
  18.  Perkins DO, Gu H, Weiden PJ, McEvoy JP, Hamer RM, Lieberman JA. 
Predictors of treatment discontinuation and medication nonadherence 
in patients recovering from a first episode of schizophrenia, 
  schizophreniform disorder, or schizoaffective disorder: a randomized, 
double-blind, flexible-dose, multicenter study. J Clin Psychiatry. 2008; 
69(1):106–113.
  19.  American Psychiatric Association. Practice guideline for the   treatment 
of patients with schizophrenia [updated 2004]. Available from: 
http://www.psychiatryonline.com/pracGuide/loadGuidelinePdf.
aspx?file=Schizophrenia2ePG_05-15-06. Accessed January 21, 
2010.
  20.  National Institute of Clinical Excellence. Core interventions in the 
treatment and management of schizophrenia in primary and secondary 
care (Clinical Guideline 1) [updated 2004 Apr 12]. Available from: 
http://www.nice.org.uk.
  21.  Tandon R, Jibson MD. Extrapyramidal side effects of antipsychotic 
treatment: scope of problem and impact on outcome. Ann Clin 
  Psychiatry. 2002;14(2):123–129.
  22.  Haddad PM, Sharma SG. Adverse effects of atypical antipsychotics: 
differential risk and clinical implications. CNS Drugs. 2007;21(11): 
911–936.
  23.  De Hert M, Schreurs V, Sweers K, et al. Typical and atypical 
antipsychotics differentially affect long-term incidence rates of the 
metabolic syndrome in first-episode patients with schizophrenia:   
a retrospective chart review. Schizophr Res. 2008;101(1–3):295–303.
  24.  Arango C, Bobes J. Managing acute exacerbations of schizophrenia: 
focus on quetiapine. Curr Med Res Opin. 2004;20(5):619–626.
  25.  Buckley PF. Efficacy of quetiapine for the treatment of schizophrenia: 
a combined analysis of three placebo-controlled trials. Curr Med Res 
Opin. 2004;20(9):1357–1363.
  26.  Hellewell JSE, Cameron-Hands D, Cantillon M. Seroquel®: evidence 
for efficacy in the treatment of hostility and aggression. Schizophr Res. 
1998;29:154–155.
  27.  Leucht S, Kissling W, Davis JM. Second-generation antipsychotics for 
schizophrenia: can we resolve the conflict? Psychol Med. 2009;39(10): 
1591–1602.
  28.  Seroquel® (quetiapine fumarate) tablets – US prescribing information. 
[updated 2010]. Available from: http://www1.astrazeneca-us.com/pi/
seroquel.pdf. Accessed January 18, 2010.
  29.  AstraZeneca. Seroquel XR (quetiapine fumarate) extended release 
tablets – US prescribing information [updated 2011 Mar]. Available 
from: http://www1.astrazeneca-us.com/pi/seroquelxr.pdf. Accessed 
May 5, 2011.
  30.  Suppes T, Datto C, Minkwitz M, Nordenhem A, Walker C, Darko D. 
Effectiveness of the extended release formulation of quetiapine as 
monotherapy for the treatment of acute bipolar depression. J Affect 
Disord. 2010;121(1–2):106–115.
  31.  Peuskens J, Trivedi JK, Malyarov S, et al. Prevention of schizophrenia 
relapse with extended release quetiapine fumarate dosed once daily: 
a randomized placebo-controlled trial in clinically stable patients. 
Psychiatry (Edgemont). 2007;4(11):34–50.
  32.  Seroquel XR (quetiapine fumarate) Extended-Release Tablets – US 
prescribing information. [updated 2010]. Available from: http://www1.
astrazeneca-us.com/pi/seroquelxr.pdf. Accessed April 23, 2010.
  33.  AstraZeneca. Seroquel XR – Summary of product characteris-
tics [updated 2010]. Available from: http://www.medicines.ie/
medicine/13032/SPC/Seroquel+XR+50mg%2c+200mg%2c+300mg
%2c+400mg+prolonged-release+tablets/. Accessed March 5, 2010.
  34.  AstraZeneca. Seroquel XR and seroquel approved in europe for pre-
vention of recurrence of bipolar disorder [updated 2009]. Available 
from: http://www.astrazeneca.com/media/latest-press-releases/2009/
Seroquel_Bipolar_Maint_EU?itemId=7082393. Accessed January 21, 
2010.
  35.  El-Khalili N, Joyce M, Atkinson S, et al. Extended-release que-
tiapine fumarate (quetiapine XR) as adjunctive therapy in major 
depressive disorder (MDD) in patients with an inadequate response 
to ongoing antidepressant treatment: a multicentre, randomized, 
double-blind, placebo-controlled study. Int J Neuropsychopharmacol. 
2010;13(7):917–932.
  36.  Bortnick B, El-Khalili N, Banov M, et al. Efficacy and tolerability of 
extended release quetiapine fumarate (quetiapine XR) monotherapy in 
major depressive disorder: A placebo-controlled, randomized study.   
J Affect Disord. 2011;128(1–2):83–94.Neuropsychiatric Disease and Treatment 2011:7 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
563
New developments in treating schizophrenia
  37.  Bauer M, Pretorius HW, Constant EL, Earley WR, Szamosi J, 
Brecher M. Extended-release quetiapine as adjunct to an   antidepressant 
in patients with major depressive disorder: results of a randomized, 
placebo-controlled, double-blind study. J Clin Psychiatry. 2009;70(4):   
540–549.
  38.  Cutler AJ, Montgomery SA, Feifel D, Lazarus A, Åström M, Brecher M. 
Extended release quetiapine fumarate monotherapy in major depressive 
disorder: a placebo- and duloxetine-controlled study. J Clin Psychiatry. 
2009;70(4):526–539.
  39.  Weisler R, Joyce M, McGill L, Lazarus A, Szamosi J, Eriksson H. 
Extended release quetiapine fumarate monotherapy for major depressive 
disorder: results of a double-blind, randomized, placebo-controlled 
study. CNS Spectr. 2009;14(6):299–313.
  40.  Katzman MA, Brawman-Mintzer O, Reyes EB, Olausson B, Liu S, 
Eriksson H. Extended release quetiapine fumarate (quetiapine XR) 
monotherapy as maintenance treatment for generalized anxiety 
disorder: a long-term, randomized, placebo-controlled trial. Int Clin 
Psychopharmacol. 2011;26(1):11–24.
  41.  Merideth C, Cutler A, Neijber A, She F, Eriksson HA. Efficacy and 
tolerability of extended release quetiapine fumarate (quetiapine XR) 
monotherapy in the treatment of generalised anxiety disorder (GAD). 
Eur Neuropsychopharmacol. 2008;18:S499.
  42.  Bandelow B, Chouinard G, Bobes J, et al. Extended-release quetiap-
ine fumarate (quetiapine XR): a once-daily monotherapy effective in 
generalized anxiety disorder. Data from a randomized, double-blind, 
placebo- and active-controlled study. Int J Neuropsychopharmacol. 
2010;13:305–320.
  43.  Khan A, Joyce M, Atkinson S, Eggens I, Baldytcheva I,   Eriksson H. 
A randomized, double-blind study of once-daily extended release 
quetiapine fumarate (quetiapine XR) monotherapy in patients with 
generalized anxiety disorder. J Clin Psychopharmacol. 2011;31: 
418–428.
  44.  AstraZeneca. Seroquel XR recommended for approval in EU as an 
add-on treatment of major depressive disorder [updated 2010].   Available 
from: http://www.astrazeneca.com/media/latest-press-releases/ 
seroquelXR-MDD?itemId=9260911. Accessed April 23, 2010.
  45.  AstraZeneca. US FDA approves seroquel XR for add-on treatment of 
major depressive disorder [updated 2009]. Available from AstraZeneca. 
Accessed January 21, 2010.
  46.  Figueroa C, Brecher M, Hamer-Maansson JE, Winter H. Pharmacokinetic 
profiles of extended release quetiapine fumarate compared with 
  quetiapine immediate release. Prog Neuropsychopharmacol Biol 
Psychiatry. 2009;33(2):199–204.
  47.  DeVane CL, Nemeroff CB. Clinical pharmacokinetics of quetiapine: 
an atypical antipsychotic. Clin Pharmacokinet. 2001;40(7):509–522.
  48.  Nemeroff CB, Kinkead B, Goldstein J. Quetiapine: preclinical studies, 
pharmacokinetics, drug interactions, and dosing. J Clin Psychiatry. 
2002;63(Suppl 13):5–11.
  49.  Datto C, Berggren L, Patel J, Eriksson HA. Self-reported sedation 
profile of immediate-release quetiapine fumarate compared with 
extended-release quetiapine fumarate during dose initiation: a random-
ized, double-blind, crossover study in healthy adult subjects. Clin Ther. 
2009;31:492–502.
  50.  Juckel G, Winter HR, Ståhle L, Miller F, Strid S. The pharmacokinetics 
of extended release quetiapine fumarate are not affected by a light 
meal. Poster presented at the 14th Biennial Winter Workshop on 
  Schizophrenia and Bipolar Disorders, Montreux, Switzerland, 
February 3–7, 2008.
  51.  Goldstein JM, Christoph G, Grimm S, Liu J, Widzowski D, 
Brecher M. Quetiapine’s antidepressant properties: direct and indirect 
  pharmacologic actions on norepinephrine and serotonin receptors. Eur 
Neuropsychopharmacol. 2007;17(Suppl 4):S401.
  52.  Seeman P. Atypical antipsychotics: mechanism of action. Can J 
  Psychiatry. 2002;47(1):27–38.
  53.  Roth BL, Sheffler D, Potkin SG. Atypical antipsychotic drug actions: 
unitary or multiple mechanisms for ‘atypicality’? Clin Neurosci Res. 
2003;3:108–117.
  54.  Kapur S, Seeman P. Antipsychotic agents differ in how fast they come 
off the dopamine D2 receptors. Implications for atypical antipsychotic 
action. J Psychiatry Neurosci. 2000;25(2):161–166.
  55.  Nyberg S, Zukin S. PET-measured occupancy of the D2 receptor: a 
comparison of quetiapine fumarate immediate- and extended-release 
formulations in healthy subjects. Poster presented at the 48th Annual 
Meeting of the American College of Neuropsychopharmacology, 
  Hollywood, Florida, USA, December 6–10, 2009.
  56.  Nyberg S, Widzowski D. Translational pharmacology of quetiapine and 
norquetiapine: preclinical findings support multifunctional psychotropic 
properties. Eur Psychiatry. 2010;25:1446.
  57.  Nyberg S, Takano A, Grimm S, et al. PET-measured D2, 5-HT2, 
and norepinephrine transporter (NET) occupancy by quetia-
pine and   N-desalkyl-quetiapine in non-human primates. Eur 
Neuropsychopharmacol. 2007;17(Suppl 4):S254–S255.
  58.  Jensen NH, Rodriguiz RM, Caron MG, Wetsel WC, Rothman RB, 
Roth BL. N-desalkylquetiapine, a potent norepinephrine reuptake 
  inhibitor and partial 5-HT(1A) agonist, as a putative mediator of 
quetiapine’s antidepressant activity. Neuropsychopharmacology. 2008; 
33(10):2303–2312.
  59.  Mamo DC, Uchida H, Vitcu I, et al. Quetiapine extended-release versus 
immediate-release formulation: a positron emission tomography study. 
J Clin Psychiatry. 2008;69(1):81–86.
  60.  Pillai A, Terry AV Jr, Mahadik SP. Differential effects of long-term treat-
ment with typical and atypical antipsychotics on NGF and BDNF levels 
in rat striatum and hippocampus. Schizophr Res. 2006;82(1):95–106.
  61.  Fumagalli F, Molteni R, Bedogni F, et al. Quetiapine regulates FGF-2 
and BDNF expression in the hippocampus of animals treated with 
MK-801. NeuroReport. 2004;15(13):2109–2112.
  62.  Xu H, Qing H, Lu W, Keegan D, Richardson JS, Li X-M. NR72: 
  quetiapine attenuates the immobilization-induced decrease of BDNF 
in rat hippocampus. Poster presented at the American Psychiatric 
Association, Philadelphia, Pennsylvania, USA, May 18–23, 2002.
  63.  Ganesan S, Agambaram V , Randeree F, Eggens I, Huizar K, Meulien D. 
Switching from other antipsychotics to once-daily extended release 
quetiapine fumarate in patients with schizophrenia. Curr Med Res Opin. 
2008;24(1):21–32.
  64.  Kahn RS, Schulz SC, Palazov VD, et al. Efficacy and tolerability of 
once-daily extended release quetiapine fumarate in acute   schizophrenia: 
a randomized, double-blind, placebo-controlled study. J Clin   Psychiatry. 
2007;68(6):832–842.
  65.  Lindenmayer JP, Brown D, Liu S, Brecher M, Meulien D. The efficacy 
and tolerability of once-daily extended release quetiapine fumarate in 
hospitalized patients with acute schizophrenia: a 6-week randomized, 
double-blind, placebo-controlled study. Psychopharmacol Bull. 2008; 
41(3):11–35.
  66.  Moller HJ, Johnson S, Mateva T, et al. Evaluation of the feasibility 
of switching from immediate release quetiapine to extended release 
quetiapine fumarate in stable outpatients with schizophrenia. Int Clin 
Psychopharmacol. 2008;23(2):95–105.
  67.  Cutler AJ, Tran-Johnson T, Kalali A, Astrom M, Brecher M,   Meulien D. 
A failed 6-week, randomized, double-blind, placebo-controlled study 
of once-daily extended release quetiapine fumarate in patients with 
acute schizophrenia: lessons learned. Psychopharmacol Bull. 2010; 
43(4):37–69.
  68.  Kalali A, Schulz SC, Kahn RS, et al. Effectiveness of once-daily 
extended release quetiapine fumarate (quetiapine XR) for excitability, 
hostility and aggression in schizophrenia. Poster 4002 presented at 
the 161st Annual Meeting of the American Psychiatric Association, 
Washington, DC, USA, May 3–8, 2008.
  69.  Leucht S, Barnes TR, Kissling W, Engel RR, Correll C, Kane JM. Relapse 
prevention in schizophrenia with new-generation antipsychotics: 
a systematic review and exploratory meta-analysis of randomized, 
  controlled trials. Am J Psychiatry. 2003;160(7):1209–1222.
  70.  Andreasen NC, Carpenter WT Jr, Kane JM, Lasser RA, Marder SR, 
Weinberger DR. Remission in schizophrenia: proposed criteria and 
rationale for consensus. Am J Psychiatry. 2005;162(3):441–449.Neuropsychiatric Disease and Treatment
Publish your work in this journal
Submit your manuscript here: http://www.dovepress.com/neuropsychiatric-disease-and-treatment-journal
Neuropsychiatric Disease and Treatment is an international, peer-
reviewed journal of clinical therapeutics and pharmacology focusing on 
concise rapid reporting of clinical or pre-clinical studies on a range of 
neuropsychiatric and neurological disorders. This journal is indexed on 
PubMed Central, the ‘PsycINFO’ database and CAS, and is the official 
journal of The International Neuropsychiatric Association (INA). The 
manuscript management system is completely online and includes a 
very quick and fair peer-review system, which is all easy to use. Visit 
http://www.dovepress.com/testimonials.php to read real quotes from 
published authors.
Neuropsychiatric Disease and Treatment 2011:7 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
Dovepress
564
Peuskens
  71.  Leucht S, Lasser R. The concepts of remission and recovery in 
  schizophrenia. Pharmacopsychiatry. 2006;39(5):161–170.
  72.  Peuskens J, Trivedi JK, Brecher M, Miller F. Long-term symptomatic 
remission of schizophrenia with once-daily extended release quetiapine 
fumarate: post-hoc analysis of data from a randomized withdrawal, 
  placebo-controlled study. Int Clin Psychopharmacol. 2010;25: 
183–187.
  73.  Meulien D, Huizar K, Brecher M. Safety and tolerability of once-daily 
extended release quetiapine fumarate in acute schizophrenia: pooled 
data from randomised, double-blind, placebo-controlled studies. Hum 
Psychopharmacol. 2010;25(2):103–115.
  74.  Boidi G, Ferro M. Rapid dose initiation of quetiapine for the treatment 
of acute schizophrenia and schizoaffective disorder: a randomised, 
multicentre, parallel-group, open study. Hum Psychopharmacol. 2007; 
22(5):299–306.
  75.  Saini SD, Schoenfeld P, Kaulback K, Dubinsky MC. Effect of 
medication dosing frequency on adherence in chronic diseases. Am J 
Manag Care. 2009;15(6):e22–e33.
  76.  Ascher-Svanum H, Faries DE, Zhu B, Ernst FR, Swartz MS, 
  Swanson JW. Medication adherence and long-term functional outcomes 
in the treatment of schizophrenia in usual care. J Clin Psychiatry. 2006; 
67(3):453–460.
  77.  Knapp M, King D, Pugner K, Lapuerta P. Non-adherence to antipsychotic 
medication regimens: associations with resource use and costs. Br J 
Psychiatry. 2004;184:509–516.
  78.  Gao K, Ganocy SJ, Gajwani P, Muzina DJ, Kemp DE, Calabrese JR. 
A review of sensitivity and tolerability of antipsychotics in patients 
with bipolar disorder or schizophrenia: focus on somnolence. J Clin 
Psychiatry. 2008;69(2):302–309.
  79.  Conley RR, Ascher-Svanum H, Zhu B, Faries DE, Kinon BJ. The 
burden of depressive symptoms in the long-term treatment of patients 
with schizophrenia. Schizophr Res. 2007;90(1–3):186–197.
  80.  McElroy SL, Weisler RH, Chang W, et al. A double-blind, placebo-
controlled study of quetiapine and paroxetine as monotherapy in adults 
with bipolar depression (EMBOLDEN II). J Clin Psychiatry. 2010; 
71(2):163–174.
  81.  Young AH, McElroy SL, Bauer M, et al. A double-blind, placebo-
controlled study of quetiapine and lithium monotherapy in adults in the 
acute phase of bipolar depression (EMBOLDEN I). J Clin Psychiatry. 
2010;71(2):150–162.
  82.  Haro JM, Novick D, Suarez D, Alonso J, Lepine JP, Ratcliffe M. 
Remission and relapse in the outpatient care of schizophrenia: three-year 
results from the schizophrenia outpatient health outcomes study. J Clin 
Psychopharmacol. 2006;26(6):571–578.